Recently, a possible relationship between C-Reactive Protein (CRP), a marker of underlying lowgrade inflammation, and mood disorders has been proposed by some researchers. The aim ofthis review is to elucidate the current facts and views about CRP in mood disorders such as Depressive and Bipolar Disorders. Several studies have examined the relationship between affective disorders and CRP, but the majority ofthe studies in literature have been limited by retrospective, case-controlled study design, and very few studies have examined the relationship between depression and CRP in large study samples. In conclusion, the role of CRP in mood disorders is, to date, intriguing but somewhat unclear. Further prospective studies are needed to introduce the CRP in clinical settings as a marker of affective states and suicidability.
Since inflammation has been proposed as an underlying process associated with atherosclerosis (1-2), the availability of highly sensitive assays for detecting minor elevations in C-Reactive Protein (CRP), a marker of underlying low-grade inflammation, has improved the ability to detect relationships between inflammation and subsequent diseases (3) . CRP is thought to assist in complement binding to foreign and damaged cells and to affect the humoral response to disease (4). It is also believed to play an important role in innate immunity, as an early defense system against infections (5).
To date, as it is widely accepted that depression is a marker for the increased risk of subsequent Coronary Heart Disease (CHD) and may be associated with an increased activation of the inflammatory system (6) (7) (8) (9) . These observations have suggested to some researchers to focus their attention on the possible interrelationships between CRP and mood disorders.
Several studies have examined the relationship between depressive symptoms and CRP, but the majority of studies in literature have been limited by retrospective, case-controlled study design, and very few studies have examined the relationship between depression and CRP in a healthy, non-elderly population (10) (11) . In a small case-controlled study, Sluzewska et al. (12) showed that CRP levels were significantly higher in patients with major depression compared with normal controls. Kop et al. (13) screened 4,268 elderly subjects for depression and CRP levels and found a significantly positive difference between depressed and non-depressed subjects; however, the difference disappeared after adjusting for other variables, including weight. Also, Timeier et al. (14) , in a case-controlled study on 263 elderly subjects with depressive symptoms, found a positive correlation between depression and CRP levels but, as in the above-mentioned study by Kop et al., this relationship disappeared after adjustment for potential confounders (smoking, stroke, functional disability and cognitive score). On the other hand, Miller et al. (15) , in a case-controlled study, found a persistently significant correlation between CRP and depression linked to a higher Body Mass Index (BMI) than control subjects. However, they also reported that when adjusting for BMI as a continuous variable, depression was no longer significantly correlated with CRP. Similar findings were also found by Ladwig et al. (16) .
Some very interesting studies were published during 2003 and 2004. In the first, Penninx et al. (17) examined the link between inflammatory markers and depressed mood in a community-based sample of 3,024 well-functioning older people. The Center for Epidemiologic Studies Depression scale (CES-D), a self-report scale to assess depressive symptoms, was employed to identify depressed mood with a cut-off of 16 or higher. The results showed that, compared with the 2,879 non-depressed subjects, 145 persons with depressed mood had higher median plasma levels of CRP (1.96 vs. 1.66 mg/L, p =.03). After dichotomizing the scores of their depression scale and stratifying the CRP levels into quartiles, they demonstrated a correlation between the depressed group and the CRP measurements. After controlling for potential confounders, including body fat mass, this relationship persisted, but only for the highest quartile of CRP levels, not for the first 3.
Steptoe et al. (18) conducted a similarly designed cross-sectional analysis examining the relationship between depression scale scores and CRP in a non clinical middle-aged population in Great
Britain. Even without controlling for confounders, the researchers found no relationship between depressive symptoms and CRP levels. Danner et al. ( 19) demonstrated an association between depression and serum CRP levels in men. Researchers analyzed data from the Third National Health and Nutrition Examination Survey (NHANES III), a representative sample of the US population from 1988 to 1994, in which the participants included a total of 6,149 individuals aged 17 to 39 years who were free from cardiovascular diseases and chronic inflammatory conditions. In particular, the results pointed out that, compared with men without a history of depression, men reporting a history of MD episodes had significantly higher odds of having elevated CRP levels after adjustment for a number of potential confounding factors. Furthermore, in contrast to the results for men, they failed to find that depression was significantly related to CRP levels in women.
One of the most interesting studies on this topic was conducted by Douglas et al. (20) in 2004. They conducted a cross-sectional study of a cohort of 696 consenting, active duty US Army personnel undergoing a periodic physical, evaluating CRP and measuring depression using the Patient Health Questionnaire-9 and the depression module of the self-administered version of the Primary Care Evaluation of Mental Disorders (PRIME-MD). The results showed that total depression scores were not independently correlated with CRP and that any correlation between depression scores and CRP was explained by a relationship with BMI. We are in agreement with the authors themselves who specified in the paper that the strengths of this study included: I) a prospective method of data collection, which is less vulnerable to bias than retrospective cohort data collection, 2) the systematic and precise measurement of variables while blinded to the status of other key variables, 3) the use of a validated depressive measurement tool with demonstrated internal validity within the population in which it was used and 4) the large size of the study which permitted the power to rigorously control for potential confounding. Another well designed and conducted study analyzed data from the Third National Health and Nutrition Examination Survey (21) and found an association between history of MD and elevated CRP levels that was present even after accounting for multiple potential confounders, but there was no indication of any association between CRP level and depression in women, despite a higher prevalence ofdepression and elevated CRP level in women than in men.
Recently, Empana et al. (22) conducted a nested case-referent study within the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study of healthy middle-aged men from Belfast and France, and evaluated the baseline CRP from 335 future cases (angina pectoris, non-fatal myocardial infarction,coronary death) and 670 matched controls (2 controls per case). They reported that men with depressive mood had CRP levels 46 percent higher than those without depressive symptoms. These results support the notion of an association ofdepressive mood with inflammatory markers and suggest that depressive mood is related to CHD even after adjustment for these inflammatory markers.
There are three studies that evaluated CRP levels during treatment of MD. Corcoran et al. (23) studied CRP and pro-and anti-inflammatory cytokines in a sample of 10 patients with resistant depression in the weeks prior to, and 3 months following, implantation of a Vagus nerve stimulator. They observed that plasma CRP levels remained unchanged after the Vagus nerve stimulation. On the other hand, Toglu et al. (24) measured TNF-alpha, CRP serum concentrations, erythrocyte sedimentation rate, and leukocyte count in 26 MD patients and in 17 controls. The measurements were repeated following 6 weeks of antidepressant treatment with selective serotonin re-uptake inhibitors. The comparison of pre-and post-treatment measurements revealed that CRP together with TNF-alpha and leukocyte count decreased to levels comparable with those of the control subjects. Lanquillon et al. (25) assessed 24 inpatients with MD both before and during 6 weeks of antidepressant (amitriptyline) treatment. They found that the levels of CRP were significantly increased at admission and decreased in both responder and nonresponder patients during anti-depressant treatment.
Finally, concerning Bipolar Disorder, there is a relative lack of studies investigating CRP levels. Hornig et al. (26) retrospectively evaluated CRP levels in 79 bipolar I, 24 bipolar II and 46 unipolar depressed outpatients in comparison to 22 healthy controls. The results showed that patients on lithium monotherapy were significantly less likely to demonstrate elevated CRP, and a similar trend was noted in those patients taking lithium in combination with an antidepressant. The frequency of elevated CRP levels did not significantly vary for different psychotropic medications, affective subgroups, or mood states. More recently, Wadee et al. (27) evaluated CRP in the sera of 45 patients each suffering from an acute manic episode compared with 45 controls and found that, although the mean CRP level was raised in the patients' group, it did not reach statistical differences from the controls.
Future research is needed to investigate the relationships between CRP levels and cytokines as, to date, no studies have evaluated such relationships in patients with mood disorders. In fact, clinical and experimental studies have indicated that stress and depression are associated with increased production of pro-inflammatory cytokines and related products, such as interleukin-l-beta (IL-l b), interleukin-6 (IL-6), IL-6 receptor (IL-6R) and interferon-gamma (IFNy) (28) (29) (30) (31) (32) (33) . In addition, longitudinal studies on clinical samples with MD or Bipolar Disorder treated with antidepressants or mood stabilizers may be useful in elucidating whether relationships between CRP and cytokines change prior to and after treatment.
Furthermore, it will be of interest in future studies to elucidate the relationships between anxiety and CRP levels, as it is reported that depression and anxiety are differentially associated with micro inflammation biomarkers such as CRP, with lower levels associated with increased anxiety, especially in the female gender (34) . Moreover, Dogan et al. (35) evaluated anxiety and depressive symptoms in forty-three hemodialysis patients and found a significant positive correlation between depression scores and CRP (r= 0.57, p < 0.001), and a significant but inverse correlation between anxiety and CRP (r=-0.43, p<0.05), confirming that lower CRP levels may be present in a condition of trait or a state of anxiety. In conclusion, the role of CRP in mood disorders is, to date, intriguing but somewhat unclear. Further prospective studies are needed to introduce the CRP in clinical settings as a marker of affective states and suicidality. 
